Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 24/2026 June 14, 2026
- Phase 2 Trial for 61Cu-NU101 vs 18F-Piflufolastat in Metastatic Prostate Cancer June 11, 2026
- UPDATE: Memantine for Neuroendocrine Prostate Cancer, Early Efficacy Signals June 9, 2026
- BRCA-Altered mCSPC Progresses Faster on ARPIs: A Real-World Treatment Gap June 9, 2026
ADVC001: Lead-212 PSMA Alpha Therapy Shows Safety and Efficacy in mCRPC Trial
/in Clinical Trial, Metastatic, Phase 1/by MaxAt the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, new clinical data from a Phase 1b dose escalation trial investigating ADVC001, a novel Lead-212-based PSMA-targeted alpha therapy for metastatic castration-resistant prostate cancer (mCRPC) was presented. The therapy utilizes a radioactive isotope, Lead-212, to deliver targeted alpha radiation to prostate cancer cells, aiming […]
Phase 3 PRESTO Trial Results: Apalutamide Extends Progression Free Survival
/in Clinical Trial, Metastatic, Phase 3/by MaxThe PRESTO trial, a phase 3 open-label study, evaluated androgen blockade intensification in patients with high-risk biochemically relapsed prostate cancer after radical prostatectomy. This population featured rapid PSA doubling times and no detectable metastases. The study randomized 504 patients to 52 weeks of treatment with either androgen deprivation therapy (ADT) alone, ADT plus apalutamide, or […]
ENZARAD Trial Shows Selective Gains for Node-Positive Prostate Cancer With Enzalutamide Intensification
/in Clinical Trial, Metastatic, Phase 3/by MaxThe final results of the phase 3 ENZARAD study, presented at the European Society for Medical Oncology (ESMO) Congress 2025, reveal that intensifying androgen deprivation therapy (ADT) with enzalutamide does not significantly improve metastasis-free survival (MFS) in the overall population of men with high-risk localized or locally advanced prostate cancer. Conducted across eight countries and […]
Pluvicto extends disease control in advanced hormone-sensitive prostate cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxThe Phase III PSMAddition trial presented at the 2025 European Society for Medical Oncology Congress marks a meaningful advance in the treatment of prostate cancer that still responds to hormonal therapy but has already spread to distant sites. In this study, patients with prostate-specific membrane antigen–positive metastatic hormone-sensitive prostate cancer received the radioligand therapy Pluvicto […]
Rapid Genome Sequencing Redefines Clinical Readiness
/in Preclinical Research/by MaxA collaboration between Broad Clinical Labs, Roche Sequencing Solutions, and Boston Children’s Hospital has set a Guinness World Record for sequencing and analyzing a whole human genome in under four hours. The record, confirmed this month and documented in the New England Journal of Medicine, demonstrates that complete genomic workflows can be completed in less […]
Phase 1/2 AlphaBet Trial: Promising Combination of Lutetium-177 PSMA-I&T and Radium-223 in Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxA novel therapeutic approach combining lutetium-177 177Lu-PSMA-I&T and radium-223 (223Ra) shows encouraging results for men with metastatic castration-resistant prostate cancer (mCRPC), as demonstrated in the recently reported AlphaBet trial published in The Lancet Oncology in October 2025. This phase 1/2 AlphaBet study is the first to evaluate the safety, feasibility, and preliminary efficacy of the […]
Real-World ARON-3 Data Highlight the Advantage of Triplet Therapy in High-Volume mHSPC
/in Retrospective studies/by MaxAt the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, pivotal real-world data from the international ARON-3 study were revealed, advancing treatment insights for high-volume metastatic hormone-sensitive prostate cancer (mHSPC) with bone metastases. The ARON-3 study evaluated 841 patients receiving either doublet therapy, combining androgen deprivation therapy (ADT) with androgen receptor pathway inhibitors […]
ARASAFE Trial Offers Safer Docetaxel-Darolutamide-ADT Regimen for mHSPC
/in Clinical Trial, Metastatic, Phase 3/by MaxRecent data presented at the 2025 European Society for Medical Oncology (ESMO) Congress reveal a promising new treatment schedule for patients with metastatic hormone-sensitive prostate cancer (mHSPC). The phase 3 ARASAFE trial evaluated an alternative docetaxel dosing regimen combined with darolutamide and androgen deprivation therapy (ADT), showing significant reductions in severe toxicities while maintaining effective […]